Head to Head Contrast: Yarrow Bioscience (NASDAQ:YARW) & Zenas BioPharma (NASDAQ:ZBIO)

Zenas BioPharma (NASDAQ:ZBIO) and Yarrow Bioscience (NASDAQ:YARW) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Zenas BioPharma and Yarrow Bioscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1	2	6	0	2.56
Yarrow Bioscience	1	0	2	0	2.33

Zenas BioPharma presently has a consensus price target of $46.71, suggesting a potential upside of 79.39%. Yarrow Bioscience has a consensus price target of $58.00, suggesting a potential upside of 327.98%. Given Yarrow Bioscience’s higher probable upside, analysts clearly believe Yarrow Bioscience is more favorable than Zenas BioPharma.

Risk & Volatility

Zenas BioPharma has a beta of -0.88, suggesting that its share price is 188% less volatile than the S&P 500. Comparatively, Yarrow Bioscience has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.

Institutional and Insider Ownership

83.8% of Yarrow Bioscience shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Zenas BioPharma and Yarrow Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-122.45%	-58.04%
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%

Earnings and Valuation

This table compares Zenas BioPharma and Yarrow Bioscience”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$1.00 million	1,697.21	-$377.74 million	($8.99)	-2.90
Yarrow Bioscience	$570,000.00	63.48	-$26.48 million	($14.64)	-0.93

Yarrow Bioscience has lower revenue, but higher earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.

Summary

Zenas BioPharma beats Yarrow Bioscience on 8 of the 14 factors compared between the two stocks.

About Zenas BioPharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

About Yarrow Bioscience

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.